|
| Status |
Public on Jun 04, 2018 |
| Title |
MeDIP-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells |
| Organism |
Homo sapiens |
| Experiment type |
Methylation profiling by high throughput sequencing
|
| Summary |
The steroid co-activator protein SRC-1 plays an important role in endocrine therapy resistant breast cancer. Its expression is associated with large high grade tumours, HER2 positivity, disease recurrence and resistance to endocrine therapy. While SRC-1 typically functions to activate gene expression, some evidence has pointed towards a potential role in repression. This study looks into the effects of a stable knockdown of SRC-1 in a tamoxifen resistant cell line, LY2, and the effects of this knock down on the methylation landscape.
|
| |
|
| Overall design |
We report the MeDIP-sequencing of tamoxifen treated LY2 breast cancer cells treated with non-targeting shRNA or SRC-1 (NCOA1) targeting shRNA and examine the methylation differences.
|
| |
|
| Contributor(s) |
Young LS, Fagan A, Ward E |
| Citation(s) |
29567811 |
| |
| Submission date |
Jun 04, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Leonie Young |
| Organization name |
Royal College of Surgeons, Ireland
|
| Department |
Surgery
|
| Lab |
Endocrine Oncology Research Group
|
| Street address |
York Street
|
| City |
Dublin |
| ZIP/Postal code |
Dublin 2 |
| Country |
Ireland |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (4)
|
|
| This SubSeries is part of SuperSeries: |
| GSE99649 |
RNA-sequencing and MeDIP-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells |
|
| Relations |
| BioProject |
PRJNA389215 |
| SRA |
SRP108576 |
Less...
More...